Vertex
Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that
multiple abstracts related to the hepatitis C virus (HCV) protease
inhibitor telaprevir and the HCV polymerase inhibitor VX-222 were
accepted for presentation at the 45th Annual Meeting of the
European Association for the Study of the Liver (EASL) in Vienna,
Austria, April 14-18, 2010. The accepted abstracts include an oral
presentation of results from Study 107, which evaluated telaprevir in
HCV patients with well-characterized prior response to HCV therapy,
including those with prior null response, partial response, viral
breakthrough or relapse. Additionally, an abstract related to results
from a Phase 1b/2a clinical trial of VX-222 in treatment-naïve genotype
1 HCV patients was accepted for oral presentation. The abstracts can be
accessed through the EASL website, www.easl.ch.
In accordance with the EASL embargo policy, the accepted abstract titles
are provided below:
“Early Virological Response Profiles with Telaprevir (T) in
Combination with Peginterferon-Alfa-2a (P) and ribavirin (R) in Genotype
1 HCV Treatment-Naïve and Treatment-Experienced Patients are Similar”
Telaprevir Oral Presentations:
1. Study 107: “SVR with Telaprevir, Peginterferon Alfa-2a and
Ribavirin in HCV Patients with Well-Characterized Prior Null Response,
Partial Response, Viral Breakthrough or Relapse After PR”; April 15,
2010, 3:45 - 4:00 p.m. CET.
2. Study C208: “On-treatment Response-guided Therapy with
Telaprevir Q8h or Q12h Combined with Peginterferon Alfa-2a or
Peginterferon Alfa-2b and Ribavirin in Treatment-naïve Genotype 1
Hepatitis C (STUDY C208)”; April 16, 2010, 4:45 - 5:00 p.m. CET.
3. Study C209: “Activity of Telaprevir Alone or in Combination
with Peginterferon Alfa-2a and Ribavirin in Treatment-naïve Genotype 2
and 3 Hepatitis-C Patients: Final Results of Study C209”; April 16,
2010. 5:00 - 5:15 p.m. CET.
VX-222 Oral Presentation:
1. “Safety and Antiviral Activity of the HCV Non-Nucleoside Polymerase
Inhibitor VX-222 in Treatment-Naïve Genotype 1 HCV-Infected Patients”;
April 15 2010, 5:00 – 5:15 p.m. CET.